Recent reports [1][2][3][4] suggest a possible association between Ad26.COV2.S (Johnson & Johnson/Janssen) COVID-19 vaccination and cerebral venous sinus thrombosis (CVST). Estimates of postvaccination CVST risk require accurate age-and sex-specific prepandemic CVST incidence rates; however, reported rates vary widely. 5 We compared the age-and sex-specific CVST rates after Ad26.COV2.S vaccination with the prepandemic CVST rate in the population.